DURECT concludes patient enrolment in Phase IIb trial of AH therapy

DURECT has concluded enrolment of patients in the Phase IIb clinical trial of larsucosterol for the treatment of severe alcohol-associated …

Emergex reports positive outcomes from naNO-DENGUE Phase I trial

Emergex Vaccines has reported positive outcomes from the naNO-DENGUE Phase I trial of DengueTcP, a T cell-priming immune set-point candidate …

VALUE-Dx initiative to tackle antimicrobial resistance in respiratory infections   

World Antimicrobial Awareness Week (WAAW) is a global campaign held annually in November to improve awareness and understanding of antimicrobial …

Baudax Bio reports promising additional data for neuromuscular blockade agent

Baudax Bio revealed additional results from a Phase II trial investigating its neuromuscular blockade (NMD) agent BX1000 in patients undergoing …

Systemic sclerosis: understanding gender differences of a complex disease

Systemic sclerosis (SSc), also known as scleroderma, is a complex autoimmune disease that affects the skin and various organs in …